Vanda Pharmaceuticals (VNDA)’ treatment of polycythemia vera was granted FDA orphan designation, according to a post to the agency’s site.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNDA:
- Vanda seeks FDA Commissioner review of Hetlioz generic ruling
- Vanda Pharmaceuticals’ Legal Victory and Potential HETLIOZ Approval Boosts Buy Rating
- Vanda Pharma granted favourable Court ruling over FDA’s Hetlioz approvability
- Strong Buy Rating for Vanda Pharmaceuticals Driven by Growth in Key Product Lines and Promising FDA Decision
- Vanda Pharmaceuticals’ Earnings Call: Growth Amid Challenges